随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
Instead, xAI seemed fixated on a range of alleged conduct of former employees. But in assessing xAI's claims, Lin said that xAI failed to show proof that OpenAI induced any of these employees to steal trade secrets "or that these former xAI employees used any stolen trade secrets once employed by OpenAI."，这一点在下载安装 谷歌浏览器 开启极速安全的 上网之旅。中也有详细论述
。关于这个话题，一键获取谷歌浏览器下载提供了深入分析
European Anti-Fraud Office to look into the former US ambassador’s time as trade commissioner in Brussels。业内人士推荐91视频作为进阶阅读
US Secretary of State Marco Rubio had said Washington was investigating the "highly unusual" incident.
Фото: Belkin Alexey / news.ru / Globallookpress.com